Institution
Beatson West of Scotland Cancer Centre
Healthcare•Glasgow, Scotland, United Kingdom•
About: Beatson West of Scotland Cancer Centre is a healthcare organization based out in Glasgow, Scotland, United Kingdom. It is known for research contribution in the topics: Cancer & Population. The organization has 489 authors who have published 1031 publications receiving 41277 citations. The organization is also known as: Beatson Oncology Centre.
Topics: Cancer, Population, Gemcitabine, Prostate cancer, Radiation therapy
Papers
More filters
QIMR Berghofer Medical Research Institute1, University of Cambridge2, University of Sydney3, University of Duisburg-Essen4, University of Erlangen-Nuremberg5, Flanders Institute for Biotechnology6, Katholieke Universiteit Leuven7, Fred Hutchinson Cancer Research Center8, Dartmouth College9, German Cancer Research Center10, University of Pittsburgh11, University of Texas at Austin12, Roswell Park Cancer Institute13, Memorial Sloan Kettering Cancer Center14, Radboud University Nijmegen15, Pomeranian Medical University16, Peter MacCallum Cancer Centre17, Princess Anne Hospital18, Stanford University19, University of South Florida20, University of California, Irvine21, University of Southern California22, University College London23, University of Michigan24, Cedars-Sinai Medical Center25, University of Hawaii26, University of Hawaii at Manoa27, Hannover Medical School28, Mayo Clinic29, University of Kansas30, University of Virginia31, Duke University32, Brigham and Women's Hospital33, Rutgers University34, Kettering University35, Oregon Health & Science University36, University of Copenhagen37, Beatson West of Scotland Cancer Centre38, Glasgow Royal Infirmary39
TL;DR: SNPs in three lncRNAs that might be important targets for novel EOC therapies are identified, including YAP1- and WWTR1 (TAZ)-stimulated gene expression and high-density lipoprotein (HDL)-mediated lipid transport pathways were associated with PFS and OS, respectively, in the cohort who had standard chemotherapy.
Abstract: PURPOSE: Chemotherapy resistance remains a major challenge in the treatment of ovarian cancer. We hypothesize that germline polymorphisms might be associated with clinical outcome. EXPERIMENTAL DESIGN: We analyzed approximately 2.8 million genotyped and imputed SNPs from the iCOGS experiment for progression-free survival (PFS) and overall survival (OS) in 2,901 European epithelial ovarian cancer (EOC) patients who underwent first-line treatment of cytoreductive surgery and chemotherapy regardless of regimen, and in a subset of 1,098 patients treated with ≥ 4 cycles of paclitaxel and carboplatin at standard doses. We evaluated the top SNPs in 4,434 EOC patients, including patients from The Cancer Genome Atlas. In addition, we conducted pathway analysis of all intragenic SNPs and tested their association with PFS and OS using gene set enrichment analysis. RESULTS: Five SNPs were significantly associated (P ≤ 1.0 × 10(-5)) with poorer outcomes in at least one of the four analyses, three of which, rs4910232 (11p15.3), rs2549714 (16q23), and rs6674079 (1q22), were located in long noncoding RNAs (lncRNAs) RP11-179A10.1, RP11-314O13.1, and RP11-284F21.8, respectively (P ≤ 7.1 × 10(-6)). ENCODE ChIP-seq data at 1q22 for normal ovary show evidence of histone modification around RP11-284F21.8, and rs6674079 is perfectly correlated with another SNP within the super-enhancer MEF2D, expression levels of which were reportedly associated with prognosis in another solid tumor. YAP1- and WWTR1 (TAZ)-stimulated gene expression and high-density lipoprotein (HDL)-mediated lipid transport pathways were associated with PFS and OS, respectively, in the cohort who had standard chemotherapy (pGSEA ≤ 6 × 10(-3)). CONCLUSIONS: We have identified SNPs in three lncRNAs that might be important targets for novel EOC therapies.
28 citations
Northwood University1, University of Birmingham2, Leicester Royal Infirmary3, Norfolk and Norwich University Hospital4, Royal Devon and Exeter Hospital5, Beatson West of Scotland Cancer Centre6, Cardiff University7, Weston Park Hospital8, University Hospital Southampton NHS Foundation Trust9, Nottingham City Hospital10, Musgrove Park Hospital11, University of Manchester12, Clatterbridge Cancer Centre NHS Foundation Trust13, The Royal Marsden NHS Foundation Trust14
TL;DR: The clinical activity of pazopanib, a multi-targeted tyrosine kinase inhibitor, was evaluated in metastatic Merkel Cell Carcinoma following a case report demonstrating benefit in patients with MCC.
Abstract: 9542Background: The clinical activity of pazopanib, a multi-targeted tyrosine kinase inhibitor, was evaluated in metastatic Merkel Cell Carcinoma (MCC) following a case report demonstrating benefit...
28 citations
TL;DR: The data provide the first in vivo experimental evidence documenting the timing of metastatic progression in CRC and suggest that genomic instability might be more important than the metastatic potential of the primary cancer in dictating CRC fate.
28 citations
Royal Free London NHS Foundation Trust1, University of Birmingham2, University of Liverpool3, Clatterbridge Cancer Centre NHS Foundation Trust4, University of Cambridge5, Beatson West of Scotland Cancer Centre6, Leicester Royal Infirmary7, Leeds Teaching Hospitals NHS Trust8, University Hospitals Bristol NHS Foundation Trust9, University of Oxford10, Norfolk and Norwich University Hospitals NHS Foundation Trust11, Hull and East Yorkshire Hospitals NHS Trust12, Great Western Hospital13
TL;DR: A national audit of UK patients treated with sorafenib as standard-of-care and those treated with systemic therapy in first-line trials found patients with ALBI grade > 1, Child-Pugh B or poor performance status seem to derive limited benefit from sorafanib treatment.
28 citations
University of Leeds1, University of Birmingham2, Imperial College Healthcare3, Cardiff and Vale University Health Board4, Beatson West of Scotland Cancer Centre5, University of Oxford6, Royal Liverpool and Broadgreen University Hospital NHS Trust7, Barts Health NHS Trust8, University of Cambridge9, University of Nottingham10, Nottingham University Hospitals NHS Trust11, University Hospital Southampton NHS Foundation Trust12
TL;DR: The Bloodwise TAP CLARITY trial combined ibrutinib with venetoclax in order to eradicate detectable CLL with the intention of stopping therapy and key secondary end-points were MRD eradication after 6 months, response by 2008 IWCLL criteria, and safety.
28 citations
Authors
Showing all 491 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Stan B. Kaye | 92 | 449 | 35666 |
| Tessa L. Holyoake | 65 | 272 | 18780 |
| Jim Cassidy | 64 | 217 | 20828 |
| John Bellamy Foster | 59 | 531 | 15649 |
| James Paul | 59 | 252 | 13394 |
| Hani Gabra | 53 | 200 | 23073 |
| Iain A. McNeish | 52 | 228 | 17880 |
| Richard H. Wilson | 50 | 188 | 8989 |
| David K. Chang | 48 | 126 | 14460 |
| Thomas J. Evans | 48 | 143 | 13144 |
| Robert Jones | 46 | 262 | 16459 |
| Nigel B. Jamieson | 44 | 131 | 10913 |
| T.R. Jeffry Evans | 41 | 113 | 7283 |
| Anthony J. Chalmers | 35 | 133 | 4254 |
| Mhairi Copland | 33 | 121 | 4795 |